Distributors, regulators cast blame for opioid epidemic

→ Trump’s last act as President (From Porter & Company) (Ad)

CHARLESTON, W.Va. (AP) — Opioid distribution companies and federal regulators pointed the finger at each other as a contributing factor in the nation's opioid epidemic during a landmark civil trial in West Virginia.

A former Drug Enforcement Administration official and the distributors each argued Wednesday that the other side disregarded requests to comply with regulations and policies, The Herald-Dispatch reported. Doing so could have led to stopping the flow of pills into local communities, they said.

The lawsuit brought by Cabell County and the city of Huntington accuses AmerisourceBergen, Cardinal Health Inc. and McKesson Corp. of fueling the epidemic. The trial is being heard in Charleston.

Joe Rannazzisi, former head of the Office of Diversion Control for the DEA from 2006 to 2015, said distributors failed to follow DEA policies.

McKesson attorney Paul Schmidt said Rannazzisi made a series of drastic changes when he took his position but did not communicate them clearly. Schmidt said distributors tried to change their monitoring policies for suspicious orders, but were ultimately unsuccessful due to the breakdown in communication.

The companies have maintained that poor communication and pill quotas set by federal agents are to blame for the epidemic, along with a rise in prescriptions written by doctors.

Should you invest $1,000 in Cardinal Health right now?

Before you consider Cardinal Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardinal Health wasn't on the list.

While Cardinal Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Cardinal Health (CAH)
4.6195 of 5 stars
$102.17-0.8%1.96%40.22Moderate Buy$102.93
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Search Headlines: